| Epsilon Healthcare Limited (EPN) ORDINARY FULLY PAID |
Health Care |
$9 |
Company Secretary Appointment/Resignation
|
27 Aug 2025 8:17AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Management Succession
|
27 Aug 2025 8:17AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Sigma Full Year FY25 Results Presentation
|
27 Aug 2025 8:17AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Sigma Healthcare Limited's merger with CW Group increased revenue and EBIT significantly.
- The company achieved a normalised revenue of $6 billion, up 82%.
- EBIT increased by 41% to $834.5 million.
- The merger completion in February 2025 facilitated financial performance improvements.
- Sigma's growth strategy includes expanding its retail network and improving product mix.
- Over 20% growth in sales of own and exclusive label products was achieved.
- Operational efficiencies and synergies are projected to reach $100 million annually by year four.
- FY26 outlook includes continued revenue growth and operational enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Sigma Full Year FY25 Results Presentation
|
27 Aug 2025 8:17AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Sigma Healthcare revenue up 82% to $6 billion.
- EBIT increased by 41% to $834.5 million.
- Pro-forma numbers assume full merger effect from July 1, 2024.
- New $1.5 billion debt facility secured until 2028.
- Net debt to normalized EBITDA ratio of 0.85x.
- CWG's PBS volumes onboarded from July 2024.
- Synergy target revised to $100 million.
- Sigma's retail network expanded in domestic and international markets.
- Over 260 Wagner health generic medicines launched.
- Sigma emerges stronger post-merger with increased scale and capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Sigma Full Year FY25 ASX Release
|
27 Aug 2025 8:17AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Normalised EBIT up 41.4%, Pro-forma EBIT of $903.4 million.
- Merger with Chemist Warehouse Group enhances scale and market reach.
- Total retail network sales up 14% to $10.3 billion.
- Synergy target upgraded to $100 million per annum.
- Year-end net debt of $752.2 million.
- Strong operating cash flow of $598.8 million.
- Dividend of 1.3 cps declared, payable on 18 September 2025.
- Own and exclusive brand strategy accelerated.
- Progressive conversion of MyChemist pharmacies to Amcal and Discount Drug Stores.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Sigma Full Year FY25 ASX Release
|
27 Aug 2025 8:17AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Merger with CWG Holdings boosted sales growth.
- Retail network sales reached $10.3 billion, up 14%.
- New Zealand sales exceeded A$1.0 billion.
- Onboarded CWG medicine supply contract, adding $2.0 billion revenue.
- Delivery volumes increased by 29% to 532 million units.
- Reduced cost to serve per unit by 11% through automation.
- Launched 269 Wagner generics medicines.
- Sales of exclusive label products up 20%.
- Synergy target increased to $100 million per annum.
- Year-end net debt was $752.2 million.
- Strong operating cash flow of $598.8 million.
- Declared a dividend of 1.3 cents per share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Appendix 4E & Full Year Financial Report
|
27 Aug 2025 8:16AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant decrease in revenue by 94% compared to the previous year.
- Net loss of AUD 4.94 million for the fiscal year ending 30 June 2025.
- Focus on commercialising the Felix™ System for assisted reproductive technology.
- Increased operational costs in research and development and marketing.
- Strategic shift towards building market presence and securing regulatory approvals.
- Emphasis on driving early revenues and establishing sustainable sales channels.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Appendix 4G and Corporate Governance Statement
|
27 Aug 2025 8:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$33,938 |
Appendix 4E & Full Year Financial Report
|
27 Aug 2025 8:16AM |
$2.820 |
$2.940 |
risen by
4.26%
|
|
SIG - Price-sensitive ASX Announcement
Full Release
Key Points
- Merger between Sigma Healthcare Limited and Chemist Warehouse completed on 12 February 2025.
- Sales revenue increased by 82.3% to $6 billion.
- Normalised EBIT reported at $834.5 million, a 41.4% increase.
- Gross margin decreased to 24% from 31.7% due to merger costs.
- Net profit after tax attributable to owners of $529.9 million.
- Significant investment in goodwill and intangible assets post-merger.
- Cash flow from operations improved, though impacted by merger-related distributions.
- Integration of Sigma and Chemist Warehouse operations across multiple regions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Annual Report to shareholders
|
27 Aug 2025 8:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Cuscal Limited (CCL) ORDINARY FULLY PAID |
Financials |
$999 |
Appendix 3Y E Proust
|
27 Aug 2025 8:16AM |
$3.520 |
$5.000 |
risen by
42.05%
|
|
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$10 |
Preliminary Final Report
|
27 Aug 2025 8:16AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
1AD - Price-sensitive ASX Announcement
Full Release
Key Points
- AdAlta Limited is focused on developing i-body platform therapeutics, particularly AD-214 for fibrotic diseases.
- The company completed all cohorts of the Phase I extension study for AD-214.
- Progress was made in manufacturing process development to support further clinical trials.
- Preclinical pipeline was expanded, notably in radiopharmaceuticals for oncology and fibrosis.
- AdAlta maintained a strategy of prudent cash management and continued seeking partnerships and funding.
- A net loss was reported for the year, reflecting R&D and operational investments.
- The report emphasizes significant clinical and corporate advancements during the period.
- AdAlta is positioning itself for further growth in the biotechnology sector.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$308 |
Change in substantial holding
|
27 Aug 2025 8:16AM |
$1.250 |
$0.885 |
fallen by
29.20%
|
|
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$33 |
Notice of change of interests of substantial holder
|
27 Aug 2025 8:16AM |
$0.038 |
$0.135 |
risen by
255.26%
|
|
| Latitude Group Holdings Limited (LFS) ORDINARY FULLY PAID |
Financials |
$936 |
Update - Notification of buy-back - LFSPA
|
27 Aug 2025 8:16AM |
$1.130 |
$0.900 |
fallen by
20.35%
|
|
| Clever Culture Systems Limited (CC5) ORDINARY FULLY PAID |
Health Care |
$35 |
APAS Contact Plate Application Product Launch
|
27 Aug 2025 8:16AM |
$0.035 |
$0.016 |
fallen by
54.29%
|
|
CC5 - Price-sensitive ASX Announcement
Full Release
Key Points
- Clever Culture Systems Limited (CCS) is a joint venture involving HiberGene Diagnostics, SARSTEDT, and bioMérieux.
- On 5 June 2024, CCS announced the launch of the APAS Contact Plate Application.
- The APAS Contact Plate Application automates the imaging, analysis, and interpretation of environmental contact plates.
- The application is targeted for use in cleanroom environments, such as pharmaceutical manufacturing and healthcare settings.
- It employs artificial intelligence to detect microbial growth and classify colonies.
- The product aims to enhance laboratory efficiency, accuracy, and regulatory compliance.
- The launch reinforces CCS’s position as an innovator in laboratory automation for microbiology.
- Supports digital transformation trends in clinical and manufacturing microbiology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flagship Minerals Limited (FLG) ORDINARY FULLY PAID |
Materials |
$53 |
Pantanillo Gold Project - Anglo Exploration Dataset Secured
|
27 Aug 2025 8:15AM |
$0.066 |
$0.155 |
risen by
134.85%
|
|
FLG - Price-sensitive ASX Announcement
Full Release
Key Points
- Flagship Minerals Limited has secured the historical AngloGold Ashanti exploration dataset for the Pantanillo Gold Project in Chile.
- The dataset includes drill logs, assay data, geophysical and geochemical surveys, and resource models.
- Access to the data enhances Flagship's geological understanding and supports more accurate exploration targeting.
- The Pantanillo Project is located in Chile's Maricunga gold belt, a region known for significant gold endowment.
- The new data will facilitate updated resource assessments and may reveal additional mineralization potential.
- This acquisition aligns with Flagship's strategy for project development and value creation.
- The company is optimistic about delivering shareholder value through accelerated exploration and improved project planning.
- The announcement highlights the strategic significance of the Pantanillo Project within Flagship's portfolio.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$29 |
AVM TO UNLOCK UNTESTED SILVER POTENTIAL AT YOQUIVO
|
27 Aug 2025 8:15AM |
$0.041 |
$0.061 |
risen by
47.56%
|
|
AVM - Price-sensitive ASX Announcement
Full Release
Key Points
- Advance Metals Limited (AVM) is focused on exploring the Yoquivo Project in Chihuahua, Mexico.
- The Yoquivo Project is located in a major silver district near significant producing mines.
- AVM has identified multiple untested silver targets within the project area.
- The company plans to undertake systematic exploration including mapping, sampling, and drilling.
- AVM aims to leverage the project's geological characteristics and historical mining activities.
- The primary objective is to identify and delineate high-grade silver mineralization.
- AVM seeks to unlock significant value for shareholders by advancing the Yoquivo Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aristocrat Leisure Limited (ALL) ORDINARY FULLY PAID |
Consumer Discretionary |
$38,377 |
Update - Notification of buy-back - ALL
|
27 Aug 2025 8:15AM |
$71.860 |
$64.020 |
fallen by
10.91%
|
|
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,689 |
Corporate Governance Statement
|
27 Aug 2025 8:15AM |
$12.930 |
$13.130 |
risen by
1.55%
|
|
| FleetPartners Group Limited (FPR) ORDINARY FULLY PAID |
Financials |
$609 |
Update - Notification of buy-back - FPR
|
27 Aug 2025 8:15AM |
$2.800 |
$2.850 |
risen by
1.79%
|
|
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,689 |
FY25 Appendix 4G
|
27 Aug 2025 8:15AM |
$12.930 |
$13.130 |
risen by
1.55%
|
|
| Flight Centre Travel Group Limited (FLT) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,689 |
Dividend/Distribution - FLT
|
27 Aug 2025 8:15AM |
$12.930 |
$13.130 |
risen by
1.55%
|
|
| EDU Holdings Limited (EDU) ORDINARY FULLY PAID |
Consumer Discretionary |
$132 |
1H25 - Appendix 4D
|
27 Aug 2025 8:14AM |
$0.478 |
$1.050 |
risen by
119.90%
|
|
EDU - Price-sensitive ASX Announcement
Full Release
Key Points
- Appendix 4D for EDU Holdings Limited for the half-year ended 31 December 2023.
- Reports an increase in revenue and net profit compared to the previous corresponding period.
- Highlights growth in student enrolments and expansion of campus network.
- Outlines principal activities in higher education and vocational training sectors.
- Provides financial summary including revenue, net profit after tax, and earnings per share.
- States no dividends have been paid or declared for the period.
- Discusses segment performance and changes in controlled entities.
- Includes directors' report, declaration, and independent auditor’s review report.
- Notes subsequent events and likely future developments in the business.
- Affirms auditor’s independence and provides a review opinion on the financial report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atturra Limited (ATA) ORDINARY FULLY PAID |
Information Technology |
$136 |
Appendix 4E and Annual Report
|
27 Aug 2025 8:14AM |
$0.800 |
$0.370 |
fallen by
53.75%
|
|
ATA - Price-sensitive ASX Announcement
Full Release
Key Points
- Atturra Limited reported strong revenue and EBITDA growth for the year ended 30 June 2023.
- The company expanded its client base and increased its workforce through both organic growth and acquisitions.
- Strategic acquisitions enhanced Atturra’s service capabilities and sector reach.
- The Board emphasized a scalable business model and robust risk management practices.
- Investment in technology, people, and processes continues to be a priority.
- Atturra remains committed to sustainability, corporate social responsibility, and sound governance.
- Dividend payments reflect confidence in the company’s ongoing performance.
- Focus areas include further sector diversification, margin improvement, and shareholder value creation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
